Interestingly, we did not find that hypoxia treatment alone traps EglN2 interaction with its known substrate HIF-1α in two ER+ breast cancer cell lines, T47D and MCF7 (Fig. 1a and Supplementary Fig. 1a). Here, EGLN2 is linked to breast carcinoma.